Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00303589 · ClinicalTrials.gov registry record · Phase 2
A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 313
- Enrollment target
NCT00303589: Completed Phase 2 study, sponsored by Hoffmann-La Roche.
NCT00303589 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 313 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (135% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00303589, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 313 participants
- Enrollment target
Study Summary
This 3 arm study will compare the efficacy and safety of beta-lactam with that of 'standard care' in patients with complicated skin and skin structure infections requiring hospitalization. Patients will be randomized to receive 1)beta-lactam 750mg iv q8h 2)beta-lactam 1500mg iv q8h or 3)'standard care' \[PRP (nafcillin or flucloxacillin) or vancomycin, plus aztreonam or ciprofloxacin\]. The anticipated time on study treatment is \<3 months and the target sample size is 100-500 individuals.
Interventions
- DRUG beta-lactam
- DRUG Standard care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 313 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
What the finished NCT00303589 record still lists
NCT00303589 is an interventional study that assigns participants to a tested intervention. The registered 313 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (135% higher).
The record links to 0 conditions, and to 2 interventions - of which beta-lactam is the first listed.
NCT00303589 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00303589 about?
NCT00303589 is a clinical study titled "A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections". This 3 arm study will compare the efficacy and safety of beta-lactam with that of 'standard care' in patients with complicated skin and skin structure infections requiring hospitalization. Patients will be randomized to receive 1)beta-lactam 750mg iv q8h 2)beta-lactam 1500mg iv q8h or 3)'standard ca...
What is the current status of trial NCT00303589?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 313 participants. The study started on 2005-12. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00303589?
The interventions under investigation include: beta-lactam (DRUG), Standard care (DRUG).
Who is sponsoring clinical trial NCT00303589?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00303589's enrollment target sits among peer trials
313 161st of 2000 higher than 1,840 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00595491 · 313 participants · Phase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
- NCT03866382 · 314 participants · Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- NCT04500756 · 314 participants · Phase 2
Limiting AAA With Metformin (LIMIT) Trial
- NCT06167746 · 314 participants · Phase 3
iCare4Me Transitions
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia